Biogen profit rises 3.2% on demand for multiple sclerosis drug

A sign marks a Biogen facility in Cambridge, Massachusetts, U.S.

Biogen Inc reported a 3.2% rise in second-quarter profit on Wednesday, getting a lift from demand for its top-selling multiple sclerosis drug Tecfidera.

Net income attributable to the company rose to $1.54 billion, or $9.59 per share, in the three months ended June 30 from $1.49 billion, or $7.85 per share, a year earlier.

Total revenue rose to $3.68 billion from $3.62 billion.

Was it worth reading? Let us know.